Table 4.
Combination of histone deacetylase inhibitors with other antitumor agents in gynecologic cancers.
| HDACi | Class | Other agents | Disease | Function | Ref. |
|---|---|---|---|---|---|
| TSA | Hydroxamic | 5-aza-2′- deoxycytidine |
Endometrial cancer | Inhibit VEGF receptors VEGFR1, VEGFR2 and Nrp1-1.85 Downregulate DNMT3B mRNA and protein expression |
[31,62,108] |
| PXD101 (belinostat) |
Hydroxamic | Carboplatin Paclitaxel |
Ovarian, epithelial and fallopian tube cancers |
Histone H4 hyperacetylation | [12,104] |
| TSA, NaB | Paclitaxel | Ovarian cancer | Induction of p53 protein | [89] | |
| TSA | Hydroxamic | Paclitaxel | Endometrial cancer | Induction of p21 Increase acetylation of tubulin and microtubule stabilization |
[41] |
| SAHA (vorinostat), NaB |
Hydroxamic, short-chain fatty acids |
Aspirin | Ovarian cancer | Induction of apoptosis | [97] |
| PXD101 (belinostat) |
Hydroxamic | Docetaxel Paclitaxel Carboplatin |
Ovarian cancer | Enhance carboplatin anticancer effect in xenograft Increase the phosphorylation of H2AX induced by carboplatin Enhance induction of histone H4 hyperacetylation |
[83] |
| SAHA | Hydroxamic | Paclitaxel | Ovarian cancer | Slightly induce apoptosis | [103 |
HDACi: Histone deacetylase inhibitor; SAHA: Suberoylanilide hydroxamic acid; TSA: Trichostatin.